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A B S T R A C T
Background: Hepatic membrane transporters are involved in the transport of many endogenous and exogenous
compounds, including drugs. We aimed to study the relation of age with absolute transporter protein expression
in a cohort of 62 mainly fetus and newborn samples.
Methods: Protein expressions of BCRP, BSEP, GLUT1, MCT1, MDR1, MRP1, MRP2, MRP3, NTCP, OCT1,
OATP1B1, OATP1B3, OATP2B1 and ATP1A1 were quantiﬁed with LC-MS/MS in isolated crude membrane
fractions of snap-frozen post-mortem fetal and pediatric, and surgical adult liver samples. mRNA expression was
quantiﬁed using RNA sequencing, and genetic variants with TaqMan assays. We explored relationships between
protein expression and age (gestational age [GA], postnatal age [PNA], and postmenstrual age); between protein
and mRNA expression; and between protein expression and genotype.
Results: We analyzed 36 fetal (median GA 23.4 weeks [range 15.3–41.3]), 12 premature newborn (GA
30.2 weeks [24.9–36.7], PNA 1.0 weeks [0.14–11.4]), 10 term newborn (GA 40.0 weeks [39.7–41.3], PNA
3.9 weeks [0.3–18.1]), 4 pediatric (PNA 4.1 years [1.1–7.4]) and 8 adult liver samples. A relationship with age
was found for BCRP, BSEP, GLUT1, MDR1, MRP1, MRP2, MRP3, NTCP, OATP1B1 and OCT1, with the strongest
relationship for postmenstrual age. For most transporters mRNA and protein expression were not correlated. No
genotype-protein expression relationship was detected.
Discussion and conclusion: Various developmental patterns of protein expression of hepatic transporters emerged
in fetuses and newborns up to four months of age. Postmenstrual age was the most robust factor predicting
transporter expression in this cohort. Our data ﬁll an important gap in current pediatric transporter ontogeny
knowledge.
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1. Introduction
Membrane-embedded transporter proteins are crucial in handling
endogenous and exogenous compounds. More speciﬁcally, hepatic
transporters are critical determinants in drug distribution, metabolism
and biliary secretion, as they facilitate inﬂux and eﬄux of substrates
from hepatocytes, where metabolism takes place (Brouwer et al., 2015).
Children admitted to a neonatal or pediatric intensive care unit may
receive many drugs. Earlier it was shown that infants with normal
weight received on average four diﬀerent drugs, and infants with an
extreme low birth weight, often prematurely born, up to 17 drugs
(Hsieh et al., 2014). Many of these drugs are substrates for transporters
(Mooij et al., 2016a), and the expression and activity of certain trans-
porters are known to be subject to age-related changes (Brouwer et al.,
2015). An example of a transporter substrate is morphine, which is
widely used in newborns and children. Morphine is taken up into the
hepatocyte by the transporter OCT1, where it is glucuronidated mainly
by UGT2B7 (Tzvetkov et al., 2013). Data suggest lower protein ex-
pression of hepatic OCT1 in younger age groups (Hahn et al., 2017;
Prasad et al., 2016), leading to elevated plasma levels and therefore
posing a higher risk of adverse events like respiratory depression.
However, the exact developmental pattern of OCT1 in fetuses and
premature newborns is not known, while data for other transporters are
also scarce or even lacking (Brouwer et al., 2015; Mooij et al., 2016a).
In neonates and young infants, age can be deﬁned in various ways:
gestational age (GA) – reﬂecting duration of pregnancy at birth; post-
natal age (PNA) – the age after birth; and postmenstrual age (PMA) –
the combination of GA and PNA. Both GA and birth are important de-
terminants of postnatal gene expression of drug metabolizing enzymes
(Hines, 2008). We hypothesize that this also accounts for drug trans-
porters. More insight in the relative importance of these determinants
could help personalize drug dosing in this young vulnerable population.
Previously, we explored the hepatic protein expressions of 10
clinically relevant transporters in 25 liver samples from fetuses, neo-
nates and young infants (Mooij et al., 2016b). Protein expression of a
number of these transporters was related to age, and important trans-
porter-speciﬁc diﬀerences were found. While this exploratory study was
clearly informative, the sample size was too small to deﬁne transporter-
speciﬁc maturational patterns. A recent publication from Prasad et al.
describes the postnatal ontogeny of hepatic drug transporters in a wider
cohort, but the younger ages (< four months) were not well re-
presented (Prasad et al., 2016). Data on gene expression of transporters
in the younger ages are richer (Brouwer et al., 2015; Mooij et al.,
2016b), but lack of correlation between gene and protein expression
restricts us from extrapolating these ﬁndings. Thus, knowledge of
transporter protein expression is lacking for fetuses and ages up to
18 weeks PNA.
Besides ontogeny, drug transporter expression and activity can be
inﬂuenced by genetic variants, as described in adults (Prasad et al.,
2014). For SLC22A1/OCT1 a relationship with genotype was suggested
by variation in the pharmacokinetics of tramadol, an OCT1 substrate, in
preterm infants, even when in vitro data suggested developmentally
low expression (Matic et al., 2016). This is interesting as for some drug
metabolizing enzymes the interplay between development and genetics
obscures an eﬀect of genetic variation. But pediatric clinical data for
transporters substrates are scarce.
In the current study we aimed to elucidate the developmental ex-
pression patterns of various hepatic drug transporters in an expanded
cohort of mainly fetal and newborn samples up to 18weeks PNA, also
including the samples from our previous pilot study. The large variation
in GA and PNA in this cohort enabled us to analyze whether PNA or
PMA correlates strongest with transporter expression. We also in-
vestigated correlation between protein expression and mRNA expres-
sion in a subset of this cohort, and analyzed whether genotype, in ad-
dition to age, explains the variability in expression of hepatic drug
transporters. Expression patterns were compared to hepatic transporter
proteins in stably transfected cell lines (HEK293 cells expressing
OATP1B1, OATP1B3, or OCT1 and MDCKII cells expressing MDR1,
MRP2 or BCRP) in order to be used for future PBPK modeling.
2. Material and methods
2.1. Tissue samples
Post-mortem liver tissue samples from autopsy of fetuses (from
therapeutic abortions or stillbirths) and infants were provided by the
Erasmus MC Tissue Bank. Tissue was procured at the time of autopsy
within 24 h after death and snap-frozen at−80 °C for later research use.
The Erasmus MC Research Ethics Board waived the need for formal
ethics approval according to the Dutch Law on Medical Research in
Humans. Tissue was collected when parental written informed consent
for both autopsy and the explicit use of the tissue for research was
present. The samples were selected when the clinical diagnosis of the
patient was not related to hepatic problems and the tissue was histo-
logically normal (Supplemental Table 1).
Human adult liver tissue samples were a gift from Prof. G.M.M.
Groothuis (University of Groningen, Groningen, the Netherlands)
(n=3) and Prof. P. Artursson (Uppsala University, Uppsala, Sweden)
(n=5). These had been collected anonymously as surgical waste ma-
terial after partial hepatectomy because of liver metastasis. For these
samples, a no-objection clause permitted use for research purposes in
line with the Dutch guidelines on secondary use of human tissue.
2.2. Selection of hepatic transporters
Thirteen clinically relevant hepatic transporters were selected (gene
name/protein name): breast cancer resistance protein (ABCG2/BCRP),
bile salt export pump (ABCB11/BSEP), glucose transporter 1 (SLC2A1/
GLUT1), monocarboxylate transporter 1 (SLC16A1/MCT1), multidrug
resistance protein 1 (ABCB1/MDR1), multidrug resistance associated
protein (ABCC/MRP) 1, 2 and 3, sodium-taurocholate cotransporting
polypeptide (SLC10A1/NTCP), organic anion-transporting polypeptide
(SLCO/OATP) 1B1, 1B3 and 2B1, and organic cation transporter 1
(SLC22A1/OCT1). Analysis on the transporters MRP1, NTCP, OATP1B3
and OCT1 was lacking in our pilot study (Mooij et al., 2016b), but was
added in this expanded study because of their clinical relevance. We
also selected ATP1A1, which is often used as a housekeeping protein
(Prasad et al., 2016).
2.3. Protein expression
Absolute transporter protein expression of the selected hepatic drug
transporters was quantiﬁed in crude membrane fractions in all samples,
including the samples from our pilot-study, using LC-MS/MS as pre-
viously described (van de Steeg et al., 2013), with some minor mod-
iﬁcations regarding isolation of the membrane fractions (see below).
Crude membrane fractions include nuclei, mitochondria as well as the
microsomal and plasma membranes. Absolute transporter expression
was also determined in cell pellets of HEK-OATP1B1, -OATP1B3,
-OCT1, MDCKII-MDR1, -MRP2, and -BCRP cells.
Isolation of crude membrane fractions from tissue samples was
conducted as follows. Approximately 10mg liver tissue or approxi-
mately 20× 106 cells was homogenized in a hypotonic buﬀer (0.5 mM
sodium phosphate, 0.1 mM EDTA, and a cocktail of protease inhibitors
containing 2mM phenylmethylsulfonylﬂuoride, aprotinin, leupeptin,
and pepstatin) using a Potter-Elvehjem homogenizer. The homogenate
was centrifuged at 100,000g for 30min at 4 °C using a LE-80k
Centrifuge with an SW28 rotor (Beckman Coulter, Fullerton, CA, USA).
This step was repeated, and the remaining pellet containing the crude
membrane fraction was resuspended in 200 μL of isotonic buﬀer
(10mM Tris-HEPES and 250mM sucrose (pH 7.4)). A maximum of
100 μg of crude membrane protein was used for tryptic digestion.
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Samples were diluted with 2 volumes of 90% methanol. The proteins
were subsequently reduced with 0.01M dithiothreitol at 37 °C for
60min and alkylated with 0.04M iodoacetamide for 20min at room
temperature in the dark. Digestion was performed after addition of
CaCl2 (ﬁnal concentration 1 nM) and 0.5mg trypsin in 17% methanol
by diluting the solution with 50mM NH4HCO3. After overnight in-
cubation the samples were incubated for another 2 h with 0.5mg
trypsin to ensure complete digestion of the protein sample. The eﬃ-
ciency of the tryptic digestion using this protocol was previously
checked using SDS-PAGE followed by silver stain, conﬁrming complete
digestion (van de Steeg et al., 2013). Finally the protein digests were
evaporated by vacuum centrifugation (Scanvac, Ballerup, DK) and
dissolved in 100mL 15% acetonitrile containing 0.1% formic acid and
5 ngmL−1 internal standard (AQUA peptide mix, Supplemental
Table 2). Samples were analyzed using an ultraperformance liquid
chromatography coupled to a 6500 QTrap mass spectrometer (AB Sciex,
Nieuwerkerk aan den IJssel, the Netherlands). Multiple reaction mon-
itoring transitions were determined from tandem mass spectra, ob-
tained by direct infusion of 0.5 mgmL−1. Per peptide, three transitions
were chosen (Q3-1, Q3-2, and Q3-3) for quantiﬁcation and conﬁrma-
tion. A peptide labeled with 15N and 13C (AQUA peptide) was synthe-
sized (Sigma-Aldrich, Steinheim, DE) and used as an internal standard
for quantiﬁcation (Supplemental Table 2). Peak identiﬁcation and
quantiﬁcation were performed using Analyst software version 1.6.
2.4. mRNA expression
mRNA expression of the selected drug transporters was determined
in a subset of 31 samples using RNA-Sequencing (RNA-Seq). RNA was
isolated from hepatic tissue using QiaSchredder column and RNeasy
Mini kit (both Qiagen, Valencia, CA) as described by Mooij et al.
(2014). Samples with an RNA integrity number of< 5 were excluded.
The RNA-Seq experiments were performed according to the Illumina
RNA-Seq protocol (San Diego, CA). In brief, a population of poly(A)+
mRNA was selected and converted to a library of cDNA fragments
(220–450 bp) with adaptors attached to both ends, using an Illumina
mRNA-Seq sample preparation kit. The quality of the library prepara-
tion was conﬁrmed by analysis on a 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA). The cDNA fragments were then sequenced
on an Illumina HiSeq 2000 to obtain 100-bp sequences from both ends
(paired end). The resulting reads were mapped by Bowtie 2 (Langmead
and Salzberg, 2012) to the transcriptome constructed through anno-
tated genes/transcripts according to the reference human genome
GRCh37.61/hg19. The mapped reads were then assigned to transcripts
from which the expression of each transcript is estimated by RSEM (Li
and Dewey, 2011). The counts of RNA-Seq fragments were used to in-
dicate the amount of identiﬁed mRNA transcripts, presented in tran-
scripts per million (TPM) (Li and Dewey, 2011).
For each transporter we calculated the total TPM values of all mRNA
Table 1
Age distribution of study samples in each age group.
All Fetuses Preterm newborns Term newborns Pediatrics Adults
Age distribution GA NA 23.4 (15.3–41.3) weeks 30.2 (24.9–36.7) weeks 40.0 (39.7–41.3) weeks NA NA
PNA NA NA 1.0 (0.14–11.4) weeks 3.86 (0.29–18.1) weeks 4.13 (1.08–7.44) years NA
GA=gestational age, PNA=postnatal age, NA=not available.
Fig. 1. Crude membrane protein (CMP) yield per amount of hepatic tissue, presented for various age groups (A), and, for the fetal/newborn cohort, for postnatal age
(PNA) (B) and postmenstrual age (PMA) (C). ρ=Spearman's rho. *Signiﬁcant after Dunn's test (*p < 0.05).
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Fig. 2. Protein expression of hepatic transporters in fetuses (n=36), preterm newborns (n=12), term newborns (n=10), pediatrics (n=4) and adults (n=8).
*Signiﬁcant after Dunn's test (*p < 0.05, **p < 0.01, ***p < 0.001).
B.D. van Groen et al. European Journal of Pharmaceutical Sciences 124 (2018) 217–227
220
transcripts, and the TPM values of only the mRNA transcripts coding for
a full functioning protein (Ensembl genome database). Correlation with
protein levels as determined in the same sample was tested with
Spearman's rank correlation coeﬃcient.
2.5. Genetics
Single nucleotide polymorphisms (SNPs) were only selected when
mRNA and/or protein expression of our selection of transporters was
expected to be inﬂuenced, based on information in the PharmGKB da-
tabase. Liver samples of children were genotyped for these SNPs
(Supplemental Table 3). Next, within a particular genotype the eﬀect of
age was studied. Adult samples were not genotyped for logistic reasons.
Because previously the inﬂuence of haplotypes of SLCO1B1 on protein
expression was shown (Prasad et al., 2014), we studied relationships
between SLCO1B1 *1A, *1B, *4, *5, *14 and *15 and protein expres-
sion.
DNA was isolated from liver tissue according to protocol using the
DNeasy® Blood and Tissue Kit (Qiagen, Valencia, CA). DNA con-
centrations were measured on the Nanodrop® 1000 Spectrophotometer
(Thermo Fisher Scientiﬁc®). The DNA isolates were diluted in 1× TE
Buﬀer to a 10 ng μL−1 solution for SNP analysis. The SNPs were gen-
otyped according to the TaqMan® allelic discrimination assays. The PCR
program consisted of an initial denaturation and DNA polymerase ac-
tivation step at 92 °C for 20 s, followed by 40 cycles at 95 °C for 3 s and
60 °C for 30 s. All PCR reactions and post-PCR detection were per-
formed on a 7500 Fast Real-Time PCR System (software version 2.3;
Applied Biosystems).
2.6. Cell lines
HEK293 cells overexpressing SLCO1B1 *1A (NM_006446.4 referring
to wild-type; hereafter named SLCO1B1) or SLCO1B3 (NM_019844.3)
were generated as previously described by our group (van de Steeg
et al., 2013, 2015). HEK293 cells, stably overexpressing SLC22A1
(NM_003057.2), were generated in a similar way, by transfection with
pIRES puro-OCT1 (internally designed, produced by Baseclear, Leiden,
NL), applying puromycin selection pressure and selecting colonies for
further analysis. MDCKII cells stably overexpressing MDR1, MRP2 or
BCRP were licensed from The Netherlands Cancer Institute (NKI, Am-
sterdam) (Evers et al., 1998; Jonker et al., 2002, 1999).
2.7. Data and statistical analysis
Data are expressed as median (range), unless otherwise stated. The
relationship of age with protein expression levels was studied as fol-
lows: ﬁrst, diﬀerences in expression between age groups were explored.
We distinguished ﬁve age groups: fetal, premature newborn
(GA<37weeks; PNA 0–18weeks), term newborn (GA>37weeks,
PNA 0–18weeks), pediatric (1.5–18 year) and adult liver samples. Next,
in the combined ﬁrst three age groups (further referred to as fetal/
newborn cohort) the correlation between age on a continuous scale
(GA, PNA and PMA) and protein levels was assessed. Within a parti-
cular genotype the eﬀect of age on transporter protein expression was
studied as above. Relationship between mRNA expression and protein
expression were studied with correlation.
Kruskal-Wallis tests with Dunn's post hoc test were used for multiple
comparisons between age groups, and Spearman's rank correlation
coeﬃcient was used for testing correlations. Inﬂuence of gender on
transporter protein expression was tested with a Mann-Whitney U test.
A two-sided signiﬁcance level of p < 0.05 is used throughout the
paper. For Dunn's post hoc test for multiple comparisons the adjusted p-
values are reported, in which a correction for multiple testing for age
groups is applied. Statistical analyses were performed using IBM SPSS
Statistics software (SPSS Statistics for Windows, version 21.0; IBM,
Armonk, NY).
3. Results
3.1. Descriptive results
In total 71 hepatic tissue samples were available for the study, in-
cluding 25 samples of our pilot study (Mooij et al., 2016b). One sample
was detected as an outlier due to inexplicably high transporter ex-
pression and was excluded. See Table 1 for the age distribution. Gender
was known for the pediatric samples only: 35 male and 27 female. The
Tissue Bank provided only the following clinical data: GA, PNA, gender,
and main clinical diagnosis. The adult tissue was histologically normal
tissue and no additional clinical data were available, due to the anon-
ymous sample collection.
3.2. Protein expression
The selected hepatic transporter proteins were detected in nearly all
samples; in two samples MRP2 could not be detected. There was high
variability in expression between transporters and between individual
samples (Supplemental Table 4). Protein expression in males and fe-
males was similar (Supplemental Table 5). Crude membrane protein
yield per mg tissue was higher in fetuses than in term newborns
(Fig. 1A). Moreover, it was negatively correlated with PNA and PMA in
Table 2
Correlation of hepatic protein expression of transporters with age in fetal/newborn cohort.
Protein expression of GA (n=58)a GA (fetal) (n=36)b PNA (n=58)a PMA (n=58)a
ATP1A1 ρ=0.120, p=0.371 ρ=0.113, p=0.513 ρ=0.145, p=0.278 ρ=0.069, p=0.605
BCRP ρ=−0.367, p=0.005 ρ=−0.301, p=0.074 ρ=−0.345, p=0.008 ρ=−0.421, p=0.001
BSEP ρ=0.484, p < 0.001 ρ=0.230, p=0.178 ρ=0.485, p < 0.001 ρ=0.513, p < 0.001
GLUT1 ρ=−0.536, p < 0.001 ρ=−0.365, p=0.028 ρ=−0.512, p < 0.001 ρ=−0.585, p < 0.001
MCT1 ρ=−0.342, p=0.009 ρ=−0.327, p=0.052 ρ=−0.096, p=0.473 ρ=−0.345, p=0.008
MDR1 ρ=−0.047, p=0.728 ρ=−0.119, p=0.489 ρ=0.064, p=0.634 ρ=−0.046, p=0.733
MRP1 ρ=0.069, p=0.608 ρ=−0.039, p=0.822 ρ=0.176, p=0.187 ρ=0.100, p=0.453
MRP2 ρ=0.202, p=0.136 ρ=0.084, p=0.625 ρ=0.306, p=0.022 ρ=0.214, p=0.114
MRP3 ρ=0.010, p=0.942 ρ=−0.218, p=0.202 ρ=0.273, p=0.038 ρ=0.032, p=0.812
NTCP ρ=0.502, p < 0.001 ρ=0.223, p=0.190 ρ=0.453, p < 0.001 ρ=0.567, p < 0.001
OATP1B1 ρ=−0.557, p < 0.001 ρ=−0.343, p=0.041 ρ=−0.481, p < 0.001 ρ=−0.604, p < 0.001
OATP1B3 ρ=0.089, p=0.508 ρ=−0.043, p=0.804 ρ=0.090, p=0.499 ρ=0.072, p=0.589
OATP2B1 ρ=−0.135, p=0.312 ρ=−0.102, p=0.554 ρ=0.005, p=0.970 ρ=−0.092, p=0.494
OCT1 ρ=−0.206, p=0.121 ρ=−0.278, p=0.101 ρ=0.055, p=0.684 ρ=−0.175, p=0.188
ρ=Spearman correlation coeﬃcient. Bold= statistically signiﬁcant (p < 0.05). GA: gestational age, PNA: postnatal age, PMA: post-menstrual age.
a Fetal/newborn cohort.
b Only fetal samples.
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the fetal/newborn cohort (Fig. 1B and C, respectively).
3.3. Age-related transporter protein expression
Overall, protein expression was highly variable within age groups
(Fig. 2 and Supplemental Table 4). More speciﬁcally, in fetal samples,
BSEP and MDR1 protein expression was lower than in adult samples,
and for BSEP also lower than in term newborn samples. MRP1, MRP2,
MRP3 and OCT1 showed a similar developmental pattern with a lower
protein expression in fetuses and term newborns than in adults. NTCP
levels increased over the whole age range. In contrast, GLUT1 protein
levels were high in fetuses, with lower expression in term newborns,
pediatrics and adults. Similarly, OATP1B1 showed high expression in
the fetal age group and low expression in the term newborn age group,
with stable protein levels further on. Protein expression levels of
ATP1A1, BCRP, MCT1, OATP1B3 and OATP2B1 were similar in sam-
ples from all age groups.
Next, we analyzed whether GA, PNA and PMA within the fetal/
newborn cohort could partly explain the observed variability (Table 2,
Figs. 3 and 4). BSEP and NTCP expression signiﬁcantly increased with
increasing GA, PNA and PMA, whereas BCRP, GLUT1 and OATP1B1
decreased. For these transporters the strongest correlation was shown
for with PMA. MRP2 and MRP3 were only positively correlated with
PNA, and MCT1 only with GA and PMA. When only fetal samples
(postnatal age= 0) are included, the relationship between GA and
transporter expression remains statistically signiﬁcant for GLUT1 and
OATP1B1. For the other transporters no relationship between GA, PNA
or PMA and expression was found.
3.4. Correlation mRNA- and protein expression
RNA-Seq data were generated from a representative subpopulation
of 31 out of the 62 pediatric patients: 12 fetal (GA 29.7 weeks
[15.3–41.3], no PNA), 8 premature newborn (GA 34.1 weeks
[24.9–36.7], PNA 0.43 [0–8.29]), 7 term newborn (GA 40.0 weeks
[39.7–41.3], PNA 3.57 [0.29–18.1]) and 4 pediatrics (PNA 4.13 years
[1.08–7.44]). The mRNA expression levels and protein expression of
ABCB11/BSEP, SLC16A1/MCT1, ABCC2/MRP2 and SLC10A1/NTCP
were signiﬁcantly correlated when using total TPM values of all mRNA
transcripts (Supplemental Table 6). When only taking into account the
mRNA transcripts actually known to be coding for protein, the corre-
lation between mRNA expression and protein expression was lost for
SLC16A1/MCT1, but appeared for ABCB1/MDR1 (Supplemental
Table 6).
3.5. Genetic variants
Genotype results are presented in Supplemental Table 3. For
SLC22A1 1222A>G, the TaqMan assay failed for two patients, pre-
sumably due to poor quality of the DNA. All patients were successfully
genotyped for other SNPs. Protein expression was neither associated
with the selected SNPs, nor with haplotypes of SLCO1B1 (Supplemental
Table 3), also when taking into consideration age within genotype-
groups.
3.6. Cell lines
The absolute protein expression of OATP1B1, OATP1B3, OCT1,
MDR1, MRP2 and BCRP was determined in the crude membrane frac-
tions of HEK-OATP1B1, -OATP1B3, -OCT1 and MDCKII-MDR1, -MRP2,
and -BCRP cells, showing good expression proﬁles (Supplemental
Table 7).
4. Discussion
Our study expands and presents data on human hepatic transporter
protein expression in a pediatric cohort with a focus on fetal and
newborn patients up to 18 weeks of postnatal age. Together with
ﬁndings on gene expression and genetic variants in the same patient
subcohort, this study is a comprehensive analysis of ontogeny of human
hepatic drug transport in the age range where knowledge was still
lacking. Below we will discuss the main ﬁndings.
Age-related changes in protein expression were transporter depen-
dent. The results with existing data from literature are summarized in
Table 3. Apart from our previous exploratory study, the only other
published LC-MS/MS proteomics study we could identify included four
neonates (Prasad et al., 2016). At this time, due to a lack of biological
data, drug dosing in preterm and term infants is left with uncertainty
regarding the level of exposure. Similarly, in pregnant women, the level
of exposure to the fetus remains unknown. Our data may aid to opti-
mize dosing of transporter substrates in these patient populations. In-
terestingly, when looking at age groups, most diﬀerences in transporter
expression were found between the fetal and adult age groups, in-
dicating that major changes in transporter protein expression occur in
early life. For example, previously was shown that OCT1 increased from
neonatal to adult age (Hahn et al., 2017; Prasad et al., 2016). Our data
adds that also in fetal and preterm newborns the OCT1 levels are lower
than in adults. While the expression of most transporters, like OCT1, is
lower in the perinatal period than at adult age, the expression of GLUT1
is signiﬁcantly higher in the perinatal period. This likely reﬂects the
physiological high need of glucose early after conception. However, we
did not study the transporter GLUT2, which is highly expressed in the
adult liver (Karim et al., 2012). This transporter could be subject to age-
related changes, possibly explaining our ﬁndings on GLUT1. Subse-
quently, OATP1B1 is also higher in the perinatal period, and is im-
portant for the hepatic uptake of hormones like estrogens (Mooij et al.,
2016a). Importantly, the decrease in GLUT1 and OATP1B1 may also be
explained by the observed negative correlation between crude mem-
brane yield and age. Not surprisingly, ontogeny patterns are not similar
when describing transporter protein expression per membrane yield
instead of per amount of tissue. However, in literature these units are
used inconsistent. As transporter proteomic data is often used for PBPK
modeling, coming from various sources, a correction factor should be
applied when describing protein expression results per crude membrane
protein in young age groups.
Both gestational age and postnatal age may impact transporter ac-
tivity diﬀerently and independently. However, the combined eﬀect, i.e.
postmenstrual age, needs to be considered as well. Our data suggest
that dosing of transporter substrates for BCRP, BSEP, GLUT1 and
OATP1B1 is best guided by PMA in the ﬁrst months of life. Using linear
correlation is problematic in wide age ranges because this implies
continuously increasing or decreasing expression up to adult age
(Leeder and Meibohm, 2016). But as we were dealing with a limited age
range (< 18weeks PNA), we considered linear correlation the most
suitable to describe our data within this subpopulation.
Considerably more literature data on pediatric transporter mRNA
expression is available than protein expression data (Brouwer et al.,
2015). However, adults studies have shown that mRNA levels do not
always correlate well with transporter protein expression (Maier et al.,
2009; Prasad et al., 2013; Ulvestad et al., 2013), which was also shown
in a subpopulation of our cohort (n=31). Interestingly, the earlier
found ABCB1 mRNA ontogeny pattern (Mooij et al., 2014) is similar to
that for the MDR1 protein in the present study, but with a much higher
fold change, possibly explaining the lack of correlation. Also, post-
translational changes may occur introducing diﬀerences between pro-
tein expression and protein activity. For example, a previous study
Fig. 3. Transporter-speciﬁc postnatal maturation of hepatic protein expression in the fetal/newborn cohort (n=58). PNA=postnatal age.
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Fig. 4. Transporter-speciﬁc post-menstrual maturation of hepatic protein expression in the fetal/newborn cohort (n=58). PMA=post-menstrual age.
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found that the fraction of highly glycosylated OATP1B3 increased with
age (Thomson et al., 2016). Unfortunately, because we used crude
membrane fractions to measure protein expression with LC-MS/MS we
could not distinguish between glycosylated and un-glycosylated trans-
porter protein. Other techniques, e.g. Western Blot, could enable this,
but this is challenging in pediatrics as much more tissue is needed.
We could not identify a relationship between protein expression and
the selected genetic variants in our cohort, although these have been
shown earlier to impact mRNA and/or protein expression. This ﬁnding
may be explained by our low sample size, but could also partly be ex-
plained by the interplay between development and genetics. For ex-
ample, in a previous study SLC22A1 181C>T in adult samples corre-
lated with OCT1 protein expression (Nies et al., 2009) but this was not
conﬁrmed in our cohort. OCT1 expression was low in fetuses, poten-
tially obscuring a possible eﬀect of genetic variants. OATP1B1 protein
expression was stable within SLCO1B1 diplotypes. In contrast, Prasad
et al. showed higher protein expression in neonates versus older chil-
dren/adults with the SLCO1B1 *1A/*1A haplotype (Prasad et al.,
2016). Moreover, our group previously showed that the SLC22A1
genotype is related to tramadol disposition in preterm infants, similar to
adults (Matic et al., 2016). This suggests that, although protein levels
are low, the SLC22A1 genotype can result in signiﬁcant diﬀerences in
protein activity in neonates. Thus, although we did not ﬁnd a correla-
tion between interrogated SNPs and protein expression, it remains
important to include genotype when analyzing developmental patterns.
Some potential limitations of our study should be addressed. First,
our results show high inter-individual variation in transporter protein
expression, which in part remained unexplained by age, gender and
genotype. It is well possible that inﬂammation (Le Vee et al., 2011),
disease, nutrition and drugs inﬂuenced transporter expression in our
cohort. Healthy infants do not require medications like ill newborns do,
thus our cohort represents the relevant population for our intended
purpose. The relative impact of these factors, however, deserves further
study. Also, samples were snap-frozen at −80 °C for later research use
at the time of autopsy within 24 h after death, which might have in-
troduced diﬀerences in quality of tissue. These limitations warrant
careful interpretation of our data.
Nevertheless, our data help improve our understanding of drugs and
endogenous processes in human populations of diﬀerent ages.
Moreover, our data could be integrated in PBPK modeling, which might
improve prediction of pediatric drug clearance. Because diﬀerences
might exist between protein expression and protein activity, future
perspectives will be to validate these models with clinical data from
transporter substrates. Previously, we have shown the value of de-
termining absolute transporter protein expressions in transfected cell
lines for application in PBPK modeling: in vivo hepatic disposition of
rosuvastatin was predicted by scaling from individually transfected cell
lines by correcting for absolute transporter protein expression levels
(Bosgra et al., 2014). In the current study we therefore determined the
absolute expression levels of the transporter protein in selected relevant
cell lines, frequently applied in in vitro drug metabolism PK studies.
Hence, the obtained results can be incorporated into PBPK modeling to
extrapolate existing adult PK data to pediatric PK data (Barrett et al.,
2012; Hartmanshenn et al., 2016), or used as appropriate scaling fac-
tors to scale between in vitro cell lines and human hepatic expression in
adults or pediatric patients.
5. Conclusions
In conclusion, we observed various patterns in the maturation of
protein expression of a number of hepatic transporter proteins in chil-
dren up to four months. This strongly suggests that disposition of drugs
and endogenous transporter substrates is subject to age-related changes
and impacts the eﬃcacy and safety of drugs in the ﬁrst months of life.
Postmenstrual age may present the most robust method to incorporate
age-related variation in transporter protein expression in dosing
guidelines. mRNA expression as surrogate marker of transporter ac-
tivity should be carefully interpreted as correlation with protein ex-
pression is mostly lacking. Moreover, adult pharmacogenetic data
cannot be directly extrapolated to neonates and young infants. Further
study is needed to delineate the eﬀect on in vivo drug disposition and
eﬀect.
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